Treatment of tumor-bearing mice with bortezomib further increased the production of these lymphocyte-stimulatory cytokines IL-2, IL-12, and IL-15, which have significant impact on the development of a cytotoxic response mediated by CD8+T cells and NK cells. Here, IL15 is linked to neoplasm.